Pfizer Inc. (NYSE:PFE) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Monday. The brokerage presently has a $37.42 target price on the biopharmaceutical company’s stock. Vetr‘s price objective suggests a potential upside of 14.47% from the stock’s previous close.
Several other equities research analysts have also weighed in on the stock. Jefferies Group lowered shares of Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the stock from $39.00 to $36.00 in a report on Thursday, October 13th. Argus reaffirmed a “buy” rating and issued a $39.00 target price on shares of Pfizer in a report on Tuesday, October 4th. Bank of America Corp. reaffirmed a “buy” rating and issued a $40.00 target price on shares of Pfizer in a report on Tuesday, September 27th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Pfizer in a report on Monday, September 26th. Finally, Piper Jaffray Cos. set a $54.00 target price on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, August 23rd. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.63.
Shares of Pfizer (NYSE:PFE) opened at 32.69 on Monday. The company has a market capitalization of $198.29 billion, a P/E ratio of 28.98 and a beta of 0.86. Pfizer has a 12-month low of $28.25 and a 12-month high of $37.39. The company has a 50 day moving average of $33.89 and a 200-day moving average of $34.37.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The company earned $13.10 billion during the quarter, compared to analysts’ expectations of $13.01 billion. During the same quarter in the prior year, the company posted $0.56 EPS. The business’s revenue was up 10.9% on a year-over-year basis. On average, equities analysts anticipate that Pfizer will post $2.46 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Friday, November 11th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 3.67%. The ex-dividend date of this dividend is Tuesday, November 8th. Pfizer’s dividend payout ratio is presently 95.24%.
Hedge funds have recently added to or reduced their stakes in the stock. Nelson Roberts Investment Advisors LLC raised its stake in Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares in the last quarter. Stelac Advisory Services LLC bought a new stake in Pfizer during the second quarter valued at about $110,000. Tuttle Tactical Management LLC bought a new stake in Pfizer during the second quarter valued at about $117,000. Gierl Augustine Investment Management Inc raised its stake in Pfizer by 5.8% in the third quarter. Gierl Augustine Investment Management Inc now owns 3,718 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 205 shares in the last quarter. Finally, Delphi Private Advisors LLC raised its stake in Pfizer by 1.2% in the second quarter. Delphi Private Advisors LLC now owns 4,007 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 47 shares in the last quarter. 69.66% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.